Chordate Medical Holding AB (FRA:K1Z) Beta: N/A (As of Jul. 03, 2026)


FRA:K1Z Chordate Medical Holding AB FRA:K1Z
46 GF Score
Price €0.00
GF Value €0.16
! 6 Warning Signs
View Full Analysis

What is Chordate Medical Holding AB Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-03), Chordate Medical Holding AB's Beta is Not available.

Chordate Medical Holding AB  (FRA:K1Z) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Chordate Medical Holding AB Beta Related Terms

Chordate Medical Holding AB Beta Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB Beta Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 8.85 7.25
FRA:K1Z
46GF Score
Chordate Medical Holding AB FRA:K1Z
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Chordate Medical Holding AB (FRA:K1Z) Overvalued in 2026?

Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued. The current stock price of €0.00 is trading 99.4% below its estimated GF Value™ of €0.16.

Key valuation signals for FRA:K1Z:

  • Beta: N/A
  • GF Value™: €0.16 vs. price of €0.00 (99.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the FRA:K1Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for FRA:K1Z

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price
€0.16
GF Value